EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-ND 4.0

Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada

Brenda Carolina Guerra-Alejos, Youwei Yan, Megan Kurz, Nishan Mudalige, Jeong Eun Min, Fahmida Homayra, Bohdan Nosyk iD

Addiction · 2024

DOI: 10.1111/add.16491 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Addiction, 2024. Verfasst von Brenda Carolina Guerra-Alejos und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Practice Patterns, Physicians', Methadone, Opiate Substitution Treatment, Opioid-Related Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDA NIH HHS, National Institutes of Health/National Institute on Drug Abuse, CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aim In British Columbia, Canada, clinical guidelines for the treatment of opioid use disorders (OUD) were updated in 2017, during a period in which the potency and composition of the illicit drug supply changed rapidly. We aimed to describe changes in opioid agonist treatment (OAT) prescribing practices at the population level in a setting in which fentanyl and its analogs have become the primary illicit opioid of use. Design, setting and participants This was a population‐based retrospective cohort study using three linked health administrative databases in British Columbia (BC), Canada. All individuals with at least one OAT dispensation in BC between 1 January 2014 and 31 August 2021 took part.

Measurements

To assess changes in OAT prescribing practices over time, we calculated initiation doses, dose titration intervals, maintenance doses and take‐home dosing intervals stratified by medication [methadone, buprenorphine–naloxone and slow‐release oral morphine (SROM)] according to recommended guidelines.

Findings

A total of 265 410 OAT episodes (57.5% on methadone, 34.5% on buprenorphine–naloxone and 8.0% on SROM) were initiated during the study period. Compared with the guideline recommendation, observed initiation doses were higher among all medications from 2014 (2017 for SROM) to 2021 (buprenorphine–naloxone: 14–29%; methadone: 53–66%; SROM: 26–55%). Titration intervals were shorter for all medications, consistent with guidelines for buprenorphine–naloxone (26–49%), but shorter than recommended for methadone or SROM (28–51% and 12–41%, respectively). Higher maintenance dosing was observed for methadone (68–78%) and SROM (3–21%). Take‐home allowances extending beyond the recommended guideline length increased across medications (buprenorphine–naloxone: 18–35%; methadone: 50–64%; SROM: 34–39%). Changes in prescribing patterns were similar for first‐time OAT initiators.

Conclusion

In British Columbia, Canada, from 2014 to 2021, prescribers of opioid agonist treatment (OAT) appeared to initiate both new and experienced OAT clients at higher doses than guideline recommendations, titrate them more rapidly and maintain clients at higher doses. Take‐home dose allowances also gradually increased.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Practice Patterns, Physicians'MethadoneOpiate Substitution TreatmentOpioid-Related DisordersGuideline AdherenceAnalgesics, OpioidHumansBritish ColumbiaRetrospective StudiesMaleFemaleAdultMiddle AgedBuprenorphine, Naloxone Drug CombinationMorphinePractice Guidelines as Topic

Stichwörter der Autor:innen

Buprenorphine/naloxoneguideline compliancemethadoneopioid agonist treatmentprescribing practicesslow‐release oral morphine

Substanzen

MethadoneAnalgesics, OpioidBuprenorphine, Naloxone Drug CombinationMorphine

Autor:innen und Institutionen

  • Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada.
  • Faculty of Health Sciences, Simon Fraser University, Vancouver, British Columbia, Canada.

ORCID-Profile: Bohdan Nosyk

Förderung

  • NIDA NIH HHS
  • National Institutes of Health/National Institute on Drug Abuse
  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Guerra-Alejos, B. C., Yan, Y., Kurz, M., Mudalige, N., Min, J. E., Homayra, F., & Nosyk, B. (2024). Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada. Addiction. https://doi.org/10.1111/add.16491

Vancouver

Guerra-Alejos BC, Yan Y, Kurz M, Mudalige N, Min JE, Homayra F, et al. Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada. Addiction. 2024. doi:10.1111/add.16491

BibTeX
@article{GuerraAlejos2024,
  author = {Guerra-Alejos, Brenda Carolina and Yan, Youwei and Kurz, Megan and Mudalige, Nishan and Min, Jeong Eun and Homayra, Fahmida and Nosyk, Bohdan},
  title = {Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada},
  journal = {Addiction},
  year = {2024},
  doi = {10.1111/add.16491}
}
Kostenlos starten →